| Literature DB >> 26787852 |
Anna-Maria Rolle1, Mike Hasenberg2, Christopher R Thornton3, Djamschid Solouk-Saran2, Linda Männ2, Juliane Weski2, Andreas Maurer1, Eliane Fischer4, Philipp R Spycher4, Roger Schibli4, Frederic Boschetti5, Sabine Stegemann-Koniszewski6, Dunja Bruder6, Gregory W Severin7, Stella E Autenrieth8, Sven Krappmann9, Genna Davies3, Bernd J Pichler1, Matthias Gunzer10, Stefan Wiehr11.
Abstract
Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease caused by the fungus Aspergillus fumigatus, and is a leading cause of invasive fungal infection-related mortality and morbidity in patients with hematological malignancies and bone marrow transplants. We developed and tested a novel probe for noninvasive detection of A. fumigatus lung infection based on antibody-guided positron emission tomography and magnetic resonance (immunoPET/MR) imaging. Administration of a [(64)Cu]DOTA-labeled A. fumigatus-specific monoclonal antibody (mAb), JF5, to neutrophil-depleted A. fumigatus-infected mice allowed specific localization of lung infection when combined with PET. Optical imaging with a fluorochrome-labeled version of the mAb showed colocalization with invasive hyphae. The mAb-based newly developed PET tracer [(64)Cu]DOTA-JF5 distinguished IPA from bacterial lung infections and, in contrast to [(18)F]FDG-PET, discriminated IPA from a general increase in metabolic activity associated with lung inflammation. To our knowledge, this is the first time that antibody-guided in vivo imaging has been used for noninvasive diagnosis of a fungal lung disease (IPA) of humans, an approach with enormous potential for diagnosis of infectious diseases and with potential for clinical translation.Entities:
Keywords: Aspergillus fumigatus; PET; aspergillosis; imaging; immunoPET/MR
Mesh:
Substances:
Year: 2016 PMID: 26787852 PMCID: PMC4776455 DOI: 10.1073/pnas.1518836113
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205